Personalized Accelerated ChEmoRadiation (PACER) for Lung Cancer

Stanford University

Status and phase: Enrolling; Phase 1

Conditions: Lung Cancer

Treatments: Radiation: Hypofractionated accelerated radiation therapy

Study type: Interventional

Funder types: Other

Identifiers

NCT06080061

IRB-71744

NCI-2024-00696 (Registry Identifier)

Details and patient eligibility

About

The purpose of this study is to examine the use of hypofractionated accelerated radiation therapy (HART) to treat locally advanced lung cancer. Depending on the location and size of the tumor.

Enrollment: 45 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Histologically or cytologically documented malignancy of the lung including non-small cell lung cancer or small cell lung cancer planned for definitive therapy with fractionated radiation (60-66 Gy) and concurrent systemic therapy
• ECOG performance status of 0-2
• Age > 18 years old
• Ability to understand and the willingness to personally sign the written IRB approved informed consent document
• Estimated life expectancy of 12 weeks or longer

Exclusion criteria

• Contraindication to receiving radiotherapy or systemic therapy as determined by treating radiation and medical oncologist
• Age < 18 years old
• Tumor directly invading the major pulmonary arteries, aorta, heart or proximal bronchial tree
• Diagnosis of interstitial pulmonary fibrosis
• Previous radiation therapy to the thorax that would result in overlapping high dose radiation fields

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

45 participants in 1 patient group

Hypofractionated accelerated radiation therapy (HART)

Experimental group

Description:

Patients will either be treated with 60-66 Gy in 30, 25, or 20 fractions based on ability to meet constraints to key organs at risk

Treatment:

Radiation: Hypofractionated accelerated radiation therapy